he market opened about 0.7% higher on Wednesday, still riding last night’s GDP optimism, but today’s tape is pure stock picker territory. I walk through why SIA’s 3.7 million June passengers and 6.3% growth are great operationally yet do not settle the income-quality question around specials versus core cashflow, especially if you are leaning on that dividend for CPF or SRS. We then unpack a S$2.13 billion Bayshore bid that will reshape an entire east coast rental story, Lum Chang’s double‑header of a new Teck Ghee Station contract and a mainboard move, and CLAR’s 32%‑premium data centre divestment that screams strong capital recycling without getting a shortcut zone verdict. Along the way I clean up the Foundation Healthcare versus Fullerton Healthcare naming confusion and admit openly where the AEM work is still on my own to‑do list instead of pretending there is a view.
Key takeaways:
SIA and Scoot carried 3.7 million passengers in June, up 6.3% year on year, but dividend reliability still hinges on the mix of specials versus core business.
A Frasers Property‑led consortium topped the Bayshore bid at about S$2.13 billion, S$1,323 psf ppr, setting up up to 1,280 new homes over Bedok South MRT and a fresh retail story.
Lum Chang secured a S$32.9 million Teck Ghee Station contract and saw Lum Chang Creations move from Catalist to the mainboard on the same day, a rare double headline for this name.
CapitaLand Ascendas REIT is divesting Kim Chuan Telecommunications Complex for about S$200.4 million, double the S$100 million 2005 purchase price and roughly 32% above last month’s valuation, a textbook capital recycling result without a formal zone call.
Foundation Healthcare’s stabilising manager bought another 850,000 shares after an earlier 4.5 million purchase, and we confirm clearly it is a different company from Fullerton Healthcare, closing that loop for listeners.
Iggy’s Forensic Disclaimer
This content is produced for educational and informational purposes only. I am not a financial advisor — I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered. Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle; stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst — these carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors. All data is sourced from public filings and verified sources; where data is unverified it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.
